Product name: gp100 (210M) peptide

Sequence: IMDQVPFSV

Purity: 95% by HPLC

Counter ion: Trifluoacetate

Format: Lyophilized powder

Description: A peptide derived from gp100 (a lineage-restricted antigen) has been synthesized in a mutated (heteroclitic) form for the purpose of enhancing HLA-A2.1 binding. This peptide, gp100:209-217(210M) binds with a higher affinity to HLA-A2 than the native peptide and induces better T-cell stimulation in vitro and in vivo. Initial clinical trials at the National Cancer Institute (NCI) with 210M demonstrated induction in peripheral blood of peptide- and tumor-specific cytotoxic T-lymphocyte responses in 10 of 11 patients with HLA-A2.1–positive melanoma, although no definitive antitumor activity was observed.

Usage: For Scientific Research Use Only, Not for Human Use.

Reference:

PLoS One. 2014; 9(4): e93231.

 

J Clin Oncol. 2008 May 10;26(14):2292-8.